TAK-33 inhibited and regressed tumor growth in melanoma cell lines and patient-derived xenograft models. This "robust" success in the lab, according to a study published in Nov. 5, 2014 in Molecular Cancer Therapeutics, justifies continued clinical development as a potential therapy for melanoma patients. » Learn more
Advanced BCC may be more common in elderly patients but many cannot tolerate surgery or radiation. Many elderly patients have comorbidities and limitations that limit therapeutic options for aBCC. » Novel options to help manage aBCC
Advances in systemic therapy, including targeted approaches and immunotherapy options, are changing the landscape of management for patients with metastatic and advanced skin cancer. » What's the dermatologist's role?
Like
Tweet
